Online citations, reference lists, and bibliographies.
← Back to Search

Solid Lipid Nanoparticles: An Oral Bioavailability Enhancer Vehicle

H. Harde, Manasmita Das, S. Jain
Published 2011 · Materials Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: The therapeutic efficacy of perorally administered drugs is often obscured by their poor oral bioavailability (BA) and low metabolic stability in the gastrointestinal tract (GIT). Solid lipid nanoparticles (SLNs) have emerged as potential BA enhancer vehicles for various Class II, III and IV drug molecules. Area covered: This review examines the recent advancements in SLN technology, with regards to oral drug delivery. The discussion critically examines the effect of various key constituents on SLN absorption and their applications in oral drug delivery. The relationship between the complexity of absorption (and various factors involved during absorption, including particle size), stability and the self-emulsifying ability of the lipids used has been explored. Expert opinion: The protective effect of SLNs, coupled with their sustained/controlled release properties, prevents drugs/macromolecules from premature degradation and improves their stability in the GIT. An extensive literature survey reveals that direct peroral administration of SLNs improves the BA of drugs by 2- to 25-fold. Overall, the ease of large-scale production, avoidance of organic solvents and improvement of oral BA make SLNs a potential BA enhancer vehicle for various Class II, III and IV drugs.
This paper references
10.1016/S0378-5173(96)04731-X
Biodegradation of solid lipid nanoparticles as a function of lipase incubation time
R. Mueller (1996)
10.1080/10837450600561182
Influence of the Formulation for Solid Lipid Nanoparticles Prepared with a Membrane Contactor
Assma Ahmed El-Harati (2006)
10.1016/S0378-5173(02)00684-1
Cosmetic applications for solid lipid nanoparticles (SLN).
S. Wissing (2003)
10.1016/J.JCONREL.2006.08.013
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
A. des Rieux (2006)
10.1023/A:1012029517394
The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual
A. Florence (2004)
10.3109/03639045.2010.539231
In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain
Lucia Montenegro (2011)
10.1016/0378-5173(94)00347-8
Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix
K. Westesen (1995)
10.1016/0168-3659(94)90047-7
Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization
C. Schwarz (1994)
10.1016/j.ejps.2010.10.002
Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting.
M. R. Aji Alex (2011)
absorption of quercetin by solid lipid nanoparticles
(2009)
10.1080/03639040802130061
Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery.
M. Muchow (2008)
10.1080/10611860902718672
Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement
Baboota Sanjula (2009)
An excellent summary on absorption of SLNs from a different segment of the GIT
10.1016/J.IJPHARM.2006.07.026
Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin.
N. Zhang (2006)
an oral bioavailability enhancer vehicle 1422 Expert Opin
H Li (2011)
10.1166/JBN.2009.1042
Lipid nanomedicines for anticancer drug therapy.
A. Estella-Hermoso de Mendoza (2009)
10.1016/j.nano.2008.08.003
Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.
Rishi Paliwal (2009)
10.1016/S0378-5173(99)00426-3
Comparison of wax and glyceride solid lipid nanoparticles (SLN).
V. Jenning (2000)
10.1016/j.ijpharm.2011.02.064
Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration.
Cheng-feng Luo (2011)
10.1021/la802199p
Temperature scanning ultrasonic velocity study of complex thermal transformations in solid lipid nanoparticles.
T. Awad (2008)
10.1016/j.jconrel.2008.10.002
Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles.
Houli Li (2009)
Preparation of solid lipid nanoparticles Harde
C Charcosset (2005)
Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
KK Rao (2007)
10.1080/10611860410001693706
Issues in Oral Nanoparticle Drug Carrier Uptake and Targeting
A. Florence (2004)
10.1016/J.JCONREL.2005.06.006
Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration.
K. Manjunath (2005)
10.1016/j.jconrel.2010.09.003
Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Ashay Jain (2010)
10.2174/138920107779941444
Recent developments in tumor angiogenesis.
W. Kilarski (2007)
Medication vehicles made of solid lipid particles (solid lipid nanospheres sln)
룩크스 스테판 (1992)
10.1002/CHIN.200748265
Stability of Lipid Excipients in Solid Lipid Nanoparticles
A. Radomska-Soukharev (2007)
Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides. PCTIB2007000896
K K Rao (2007)
10.1016/J.TUBE.2005.08.009
Oral solid lipid nanoparticle-based antitubercular chemotherapy.
R. Pandey (2005)
10.1016/S0928-0987(97)86243-4
Solid lipid nanoparticles (SLN) for controlled drug delivery
R. Mueller (1996)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
Lipospheres for controlled delivery of substances
AJ Domb (1993)
Methods for producing solid lipid microparticles having a narrow size distribution
MR Gasco (1993)
tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration
Pharmacokinetics (2011)
10.1023/A:1011975120776
Solid Lipid Nanoparticles in Lymph and Plasma After Duodenal Administration to Rats
A. Bargoni (2004)
10.2174/1389201053167158
The impact of nanobiotechnology on the development of new drug delivery systems.
O. Kayser (2005)
Solid lipid nanoparticles as delivery systems for bioactive food components. Food Biophys 2008;3:146-54 .. This article gives suggestion on application of SLNs in the delivery of bioactive foods
J Weiss (2008)
Preparation of solid lipid nanoparticles Harde , Das & Jain Expert Opin
C Charcosset (2011)
10.1016/0168-3659(95)00059-H
Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate
A. T. Florence (1995)
10.1016/J.EJPB.2005.03.006
Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier.
M. Schubert (2005)
10.1016/J.COLSURFB.2007.03.002
Studies on oral absorption of stearic acid SLN by a novel fluorometric method.
H. Yuan (2007)
Enhancement of gastrointestinal Solid lipid nanoparticles : an oral bioavailability enhancer vehicle 1422 Expert Opin
H Li (2011)
10.1002/JPS.10368
Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin.
R. Cavalli (2003)
Lipid nano pellets as drug carriers for oral administration
P. Speiser (1986)
10.1007/S11483-008-9065-8
Solid Lipid Nanoparticles as Delivery Systems for Bioactive Food Components
J. Weiss (2008)
Solid lipid nanoparticles (SLN) : an alternative colloidal carrier system for controlled drug delivery
R. Mueller (1995)
10.1016/j.jconrel.2008.02.007
Design and production of nanoparticles formulated from nano-emulsion templates-a review.
N. Anton (2008)
10.1248/CPB.49.1444
In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel.
D. Chen (2001)
This article gives suggestion on application of SLNs in the delivery of bioactive foods
10.2217/nnm.10.42
Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles.
Shuyu Xie (2010)
10.1016/J.IJPHARM.2005.06.025
Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting.
T. Göppert (2005)
10.1002/JPS.10129
Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
G. Zara (2002)
10.1080/10611860600888850
Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration
K. Manjunath (2006)
10.1208/pt0801024
Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles
G. Suresh (2008)
10.1016/0169-409X(91)90048-H
Peroral administration of nanoparticles
J. Kreuter (1991)
10.1016/J.JCONREL.2005.07.023
Preparation of solid lipid nanoparticles using a membrane contactor.
C. Charcosset (2005)
10.1080/03639040802130061
Lipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug Delivery
M. Muchow (2008)
10.1358/MF.2005.27.2.876286
Solid lipid nanoparticles as drug delivery systems.
K. Manjunath (2005)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1016/j.colsurfb.2010.12.014
Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids.
Shuyu Xie (2011)
10.1016/S0378-5173(97)04885-0
Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters
A. J. Almeida (1997)
10.1016/S0168-3659(97)01653-2
Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes
R. Mueller (1997)
[In vitro and in vivo study of two kinds of long-circulating solid lipid nanoparticles containing paclitaxel].
D. Chen (2002)
10.1016/J.EJPB.2007.07.006
Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation.
R. Mueller (2008)
Preparation of Solid Lipid Nanoparticles Loading Matrine
Lv Ji (2013)
10.1016/j.ijpharm.2010.08.014
Production & stability of stavudine solid lipid nanoparticles--from lab to industrial scale.
R. Shegokar (2011)
10.1016/J.PHRS.2004.10.007
The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle.
Zhinan Mei (2005)
10.1016/J.ADDR.2007.04.005
Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.
A. Hanafy (2007)
10.1023/A:1018888927852
Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration
Shicheng Yang (2004)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1208/pt0804083
Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles
K. Vivek (2008)
Functionalized solid lipid nanoparticles and methods of making and using same
VP Shastri (2006)
10.1211/0022357044959
Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs
L. Hu (2004)
10.1016/S0939-6411(98)00074-5
Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase.
C. Freitas (1999)
10.1016/0169-409X(90)90020-S
Intestinal translocation of particulates — implications for drug and antigen delivery
D. O'hagan (1990)
10.1016/j.colsurfb.2010.12.024
The size of solid lipid nanoparticles: an interpretation from experimental design.
Carla Vitorino (2011)
10.1023/A:1016085108889
Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
M. P. Desai (2004)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1208/s12249-010-9410-3
Preparation and Enhanced Oral Bioavailability of Cryptotanshinone-Loaded Solid Lipid Nanoparticles
L. Hu (2010)
10.3109/10611869609015973
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.
R. Mueller (1996)
Targeting to intestinal M cells.
M. Jepson (1996)
10.1016/J.JCONREL.2006.05.010
Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability.
Yifan Luo (2006)
Design and production of nanoparticles formulated from nanoemulsion templatesreview
N Anton (2008)
This article compared BA of SLNs after both oral and intraduodenal administration



This paper is referenced by
10.1016/j.jconrel.2012.12.021
Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier.
A. Beloqui (2013)
10.1016/j.ijpharm.2019.02.002
Simvastatin‐loaded solid lipid nanoparticles for enhanced anti‐hyperlipidemic activity in hyperlipidemia animal model
Syed Zaki Husain Rizvi (2019)
10.1016/j.jcis.2014.04.057
Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique.
R. Shah (2014)
10.1016/j.ejpb.2016.10.007
Does the commonly used pH-stat method with back titration really quantify the enzymatic digestibility of lipid drug delivery systems? A case study on solid lipid nanoparticles (SLN).
M. Heider (2016)
10.1111/jphp.12644
Alpha‐lipoic acid–stearylamine conjugate‐based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in‐vivo pharmacokinetic and hepatotoxicity study
Ankit Dhaundiyal (2016)
10.1016/j.ijpharm.2015.05.005
Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure.
Mingzhu Shangguan (2015)
10.22377/AJP.V6I4.46
Preparation and characterization of Biochanin A loaded solid lipid nanoparticles
Chunlei Tao (2012)
10.1208/s12249-018-1284-9
Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs
Bushra Nabi (2019)
DEVELOPMENT AND IN VITRO EVALUATION OF NANOSTRUCTURED LIPID CARRIERS (NLCs) OF GLICLAZIDE
Aindrilla S Duttagupta (2016)
10.1007/s00289-020-03220-5
A novel microwave-assisted synthesis, characterization and evaluation of luliconazole-loaded solid lipid nanoparticles
M. Sharma (2020)
10.1016/j.chemphyslip.2020.104946
Improvising anti-leishmanial activity of Amphotericin B and Paromomycin using co-delivery in D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) tailored Nano-lipid carrier system.
Shabi Parvez (2020)
10.1007/s11095-015-1827-7
Glucose-Based Mesoporous Carbon Nanospheres as Functional Carriers for Oral Delivery of Amphiphobic Raloxifene: Insights into the Bioavailability Enhancement and Lymphatic Transport
Yanghuan Ye (2015)
10.2217/nnm-2016-0336
Novel surface-engineered solid lipid nanoparticles of rosuvastatin calcium for low-density lipoprotein-receptor targeting: a Quality by Design-driven perspective.
S. Beg (2017)
10.1016/B978-0-12-804305-9.00014-2
Bioavailability and delivery of nutraceuticals by nanoparticles
C. Tamer (2016)
10.1016/j.jsbmb.2019.105489
Vitamin D microencapsulation and fortification: Trends and technologies
V. K. Maurya (2020)
10.5101/nbe.v10i4.p379-391
Formulation, Characterization, in vitro Anti-Tubercular Activity and Cytotoxicity Study of Solid Lipid Nanoparticles of Isoniazid
B. C. Mohanta (2018)
10.1016/J.COFS.2014.12.005
Improving oral bioavailability of nutraceuticals by engineered nanoparticle-based delivery systems
Mingfei Yao (2015)
10.1080/10408398.2015.1031337
Solid lipid nanoparticles as oral delivery systems of phenolic compounds: Overcoming pharmacokinetic limitations for nutraceutical applications
Sara Nunes (2017)
10.1007/978-1-62703-475-3_3
Encapsulation of antioxidants in gastrointestinal-resistant nanoparticulate carriers.
E. Souto (2013)
10.3390/nano8100825
Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω-3 Fatty Acid Derivatives
Gabriela Garrastazu Pereira (2018)
10.1016/j.ijpharm.2015.04.042
Divalent toxoids loaded stable chitosan-glucomannan nanoassemblies for efficient systemic, mucosal and cellular immunostimulatory response following oral administration.
H. Harde (2015)
10.1039/C6GC00866F
Synthetic ultra-long chain fatty acyl based amphiphilic lipids as a dual function excipient for the production of surfactant-free solid lipid nanoparticles (SF-SLNs): a physico-chemical study
W. Wei (2016)
10.1080/17425247.2018.1503249
Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs
R. S. Managuli (2018)
10.1002/EJLT.201300413
Coumarin 6 as a fluorescent model drug: How to identify properties of lipid colloidal drug delivery systems via fluorescence spectroscopy?
J. H. Finke (2014)
10.1080/17425247.2016.1200554
Advances in oral delivery of anti-cancer prodrugs
A. Jain (2016)
10.1016/j.jconrel.2015.08.042
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.
Antoinette G. Nelson (2015)
10.5897/AJPP12.1470
Detection, biological effectiveness, and characterization of nanosilver-epidermal growth factor sustained-release carrier
Huiqing Xie (2013)
10.1208/s12249-019-1337-8
Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability
S. Talegaonkar (2019)
10.1016/j.addr.2016.04.001
Lipid-based nanocarriers for oral peptide delivery.
Zhigao Niu (2016)
10.1016/j.jconrel.2013.05.002
A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine.
V. Gupta (2013)
10.18632/ONCOTARGET.4091
Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action
S. Voruganti (2015)
10.1007/978-981-10-3647-7_8
Lipid Carriers: Role and Applications in Nano Drug Delivery
Naveen Chella (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar